Literature DB >> 8627175

Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors.

Y Li1, K E Hellstrom, S A Newby, L Chen.   

Abstract

Genetic modification of many types of mouse tumors to express the B7-1 or B7-2 molecules, natural ligands for the T cell-costimulatory molecule CD28, increases their immunogenicity. However, even after transfection with the B7-1 and/or B7-2 genes, poorly immunogenic tumors fail to elicit and efficient immune response. We report here that two such tumors, the Ag104A sarcoma and the K1735-M2 melanoma, become immunogenic after transfection of the genes encoding murine B7-1 together with CD48, which is the natural ligand for CD2. Tumor-specific CD8+ cytotoxic T lymphocytes were readily generated and were effective for adoptive immunotherapy of metastasis induced by wild-type Ag104A sarcoma cells. A similar approach may be useful for developing therapy for other poorly immunogenic tumors, including those in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627175      PMCID: PMC2192440          DOI: 10.1084/jem.183.2.639

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  17 in total

1.  CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells.

Authors:  D Nandi; J A Gross; J P Allison
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

Review 2.  T-cell antigen receptor genes and T-cell recognition.

Authors:  M M Davis; P J Bjorkman
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

Review 3.  The role of cell surface recognition structures in the initiation of MHC-unrestricted 'promiscuous' killing by T cells.

Authors:  D L Thiele; P E Lipsky
Journal:  Immunol Today       Date:  1989-11

4.  Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein.

Authors:  R F Siliciano; J C Pratt; R E Schmidt; J Ritz; E L Reinherz
Journal:  Nature       Date:  1985 Oct 3-9       Impact factor: 49.962

Review 5.  Costimulation of T cells for tumor immunity.

Authors:  L Chen; P S Linsley; K E Hellström
Journal:  Immunol Today       Date:  1993-10

6.  Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.

Authors:  Y Li; P McGowan; I Hellström; K E Hellström; L Chen
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

7.  Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.

Authors:  G Yang; K E Hellström; I Hellström; L Chen
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

Review 8.  The B7 and CD28 receptor families.

Authors:  C H June; J A Bluestone; L M Nadler; C B Thompson
Journal:  Immunol Today       Date:  1994-07

9.  Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival.

Authors:  L Qin; K D Chavin; J Lin; H Yagita; J S Bromberg
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

10.  Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.

Authors:  P L Ward; H Koeppen; T Hurteau; H Schreiber
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Immunotherapy II: Antigens, receptors and costimulation.

Authors:  P F Searle; L S Young
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

2.  Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16.

Authors:  I Melero; M C Singhal; P McGowan; H S Haugen; J Blake; K E Hellstrom; G Yang; C H Clegg; L Chen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 3.  Therapeutic vaccination with tumor cells that engage CD137.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Mol Med (Berl)       Date:  2003-02-08       Impact factor: 4.599

4.  Preliminary study on the cooperation of IL-6 and mB7-1 in the induction of effective antitumor immunity in vitro.

Authors:  S Qu; R Liu; Y Wang; J Wang
Journal:  J Tongji Med Univ       Date:  1999

5.  Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.

Authors:  Shilin Yang; Yi Yang; John Raycraft; Hongtao Zhang; Sandra Kanan; Yajun Guo; Ze'ev Ronai; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

Review 6.  Treatment of lymphoma with adoptively transferred T cells.

Authors:  Brian G Till; Oliver W Press
Journal:  Expert Opin Biol Ther       Date:  2009-11       Impact factor: 4.388

7.  Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.

Authors:  T Nishimura; K Iwakabe; M Sekimoto; Y Ohmi; T Yahata; M Nakui; T Sato; S Habu; H Tashiro; M Sato; A Ohta
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

8.  Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes.

Authors:  J Blake; J V Johnston; K E Hellström; H Marquardt; L Chen
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

9.  Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy.

Authors:  M Wick; P Dubey; H Koeppen; C T Siegel; P E Fields; L Chen; J A Bluestone; H Schreiber
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

10.  CD28-independent induction of T helper cells and immunoglobulin class switches requires costimulation by the heat-stable antigen.

Authors:  Y Wu; Q Zhou; P Zheng; Y Liu
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.